The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
AUTOR(ES)
Sinilnikova, O M
FONTE
Nature Publishing Group
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2768437Documentos Relacionados
- Association of XRCC1 Arg399GIn and Tp53 Arg72Pro polymorphisms and increased risk of uterine leiomyoma - A case-control study
- BRCA2 mutation carriers, reproductive factors and breast cancer risk
- Influência dos polimorfismos P53 ARG72PRO, MDM2 T309G, BCL2 C(-938)A e BAX G(-248)A, relacionados com apoptose celular, na susceptibilidade ao melanoma cutâneo = : Influence of the polymorphisms P53 ARG72PRO, MDM2 T309G, BCL2 C (-938) A and BAX G (-248) A, involved with cellular apoptosis, incutaneous melanoma susceptibility
- Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers
- The role of TP53 PRO47SER and ARG72PRO single nucleotide polymorphisms in the susceptibility to bladder cancer